Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Magro CM, A Crowson N, Morrison C, Li J. Pityriasis lichenoides chronica: stratification by molecular and phenotypic profile. Hum Pathol. 2007;38(3):479-90.

Setlur SR, Royce TE, Sboner A, Mosquera J-, Demichelis F, Hofer MD, et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res. 2007;67(21):10296-303.

Du B, Leung H, Khan KM, Miller CG, Subbaramaiah K, Falcone DJ, et al. Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an epidermal growth factor receptor dependent mechanism. Cancer Res. 2007;67(18):8966-72.

A Crowson N, Magro C, Mihm MC. Unusual histologic and clinical variants of melanoma: implications for therapy. Curr Oncol Rep. 2007;9(5):403-10.

Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007;12(2):160-70.

Pidcoke HF, Salinas J, Wanek SM, Concannon M, Loo F, Wirfel KL, et al. Patterns of exogenous insulin requirement reflect insulin sensitivity changes in trauma. Am J Surg. 2007;194(6):798-803; discussion 803.

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31(5):653-63.

Jaggi JS, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One. 2007;2(3):e267.

Rheault MN, van Burik J-, Mauer M, Ingulli E, Ferrieri P, Jessurun J, et al. Cat-scratch disease relapse in a kidney transplant recipient. Pediatr Transplant. 2007;11(1):105-9.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25(1):77-84.